SynthesisAbdominal radiology (New York)2026
Role of ADC in differentiating hepatocellular adenoma vs. hepatocellular carcinoma and metastatic liver lesions: systematic review and meta-analysis.
Synthesis in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDifferentiating hepatocellular adenoma (HCA) from malignant focal liver lesions (FLLs), including hepatocellular carcinoma (HCC), and metastases, is challenging yet clinically important. Given biopsy-associated bleeding risks in suspected HCA and differing treatment strategies, accurate noninvasive imaging biomarkers are needed.
methodsA systematic literature search of PubMed, Embase, Web of Science, and Cochrane Library up to August 10, 2025, identified studies reporting quantitative apparent diffusion coefficient (ADC) values for histologically or imaging-confirmed HCA and malignant FLLs. Data extraction and risk-of-bias assessment were performed independently by two reviewers using QUADAS-2. Random-effects meta-analysis calculated pooled mean ADC values, mean differences, standardized mean differences (SMDs), and percentage differences.
resultsSixteen studies comprising 1279 lesions (212 HCA, 697 HCC, 370 metastases) were included. Mean ADC values were 1.34 × 10⁻³ mm²/s for HCA, 1.23 × 10⁻³ mm²/s for HCC, and 1.25 × 10⁻³ mm²/s for metastases. HCA demonstrated modest yet significantly higher ADC than HCC (mean difference = 0.12 × 10⁻³ mm²/s, p = 0.042; SMD = 0.35). No significant difference was observed between HCA and metastases (mean difference = 0.17 × 10⁻³ mm²/s, p = 0.153; SMD = 0.54), likely reflecting heterogeneity in metastatic biology. Publication bias assessment was negative for all comparisons.
conclusionADC values were slightly higher in HCA than HCC but largely overlapped with metastases; given the small effect sizes and substantial unexplained heterogeneity, despite the claims by several included studies, ADC currently has only a limited, complementary role in lesion characterization and cannot reliably replace biopsy.
Indexed as
Identifiers
41483152What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.